Mechanism of glycosaminoglycan-mediated bone and joint disease: Implications for the mucopolysaccharidoses and other connective tissue diseases

American Journal of Pathology

Volumn 172, Issue 1, 2008, Pages 112-122

  Simonaro, Calogera M ^a   D'Angelo, Marina ^b   He, Xingxuan ^a   Eliyahu, Efrat ^a   Shtraizent, Nataly ^a   Haskins, Mark E ^c   Schuchman, Edward H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; COLLAGENASE 3; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LIPOPROTEIN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; SPHINGOSINE 1 PHOSPHATE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHROPATHY; ARTICLE; BONE DISEASE; BONE MARROW; CARTILAGE CELL; CAT; CELL LYSATE; CELL PROLIFERATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOG; FIBROBLAST; GENE EXPRESSION; MUCOPOLYSACCHARIDOSIS; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYNOVIUM; WESTERN BLOTTING;

EID: 38749093729     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.070564     Document Type: Article

References (44)

1. Neufeld EF, Muenzer J: The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2001, pp 3421-3452
2. Simonaro CM, Haskins ME, Schuchman EH: Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001, 81:1319-1328
3. Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH: Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005, 57:701-707
4. De Vries-Bouwstra JK, Goekoop-Ruiterman YP, Wesoly J, Hulsmans HJ, de Craen AJ, Breedveld FC, Dijkmans BA, Allaart CF, Huizinga TW: Ex vivo IL1 receptor antagonist production upon LPS stimulation is associated with development of RA and with greater progression of joint damage. Ann Rheum Dis 2007, Jan 12:[Epub ahead of print]
5. Goldring SR: Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2002, 4:406-410
6. Hemmings BA: Akt signaling: linking membrane events to life and death decisions. Science 1997, 275:628-630
7. Auclair D, Hein LK, Hopwood JJ, Byers S: Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval. Pediatr Res 2006, 59:538-543
8. Pastores GM, Meere PA: Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol 2005, 17:70-78
9. Parildar Z, Uslu R, Tanyalcin T, Doganavsargil E, Kutay F: The urinary excretion of glycosaminoglycans and heparan sulphate in lupus nephritis. Clin Rheumatol 2002, 21:284-288
10. Edward M, Fitzgerald L, Thind C, Leman J, Burden AD: Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br J Dermatol 2007, 156:473-479
11. Wang JY, Roehrl MH: Glycosaminoglycans are a potential cause of rheumatoid arthritis. Proc Natl Acad Sci USA 2002, 99:14362-14367
12. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S: Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000, 43:2523-2530
13. Nuttall JD, Brumfield LK, Fazzalari NL, Hopwood JJ, Byers S: Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif Tissue Int 1999, 65:47-52
14. Migita K, Eguchi K, Kawabe Y, Ichinose Y, Tsukada T, Aoyagi T, Nakamura H, Nagataki S: TNF-alpha mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts. Immunology 1996, 89:553-557
15. Jezyk PF, Haskins ME, Patterson DF, Mellman WJ, Greenstein M: Mucopolysaccharidosis in a cat with arylsulfatase B deficiency: a model of Maroteux-Lamy syndrome. Science 1977, 198:834-836
16. Haskins ME, Desnick RJ, DiFerrante N, Jezyk PF, Patterson DF: Beta-glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII. Pediatr Res 1984, 18:980-998
17. Yoshida M, Noguchi J, Ikadai H, Takahashi M, Nagase S: Arylsulfatase B-deficient mucopolysaccharidosis in rats. J Clin Invest 1993, 91:1099-1104
18. Haskins M, Casal M, Ellinwood NM, Melniczek J, Mazrier H, Giger U: Animal models for mucopolysaccharidoses and their clinical relevance. Acta Paediatr Suppl 2002, 9:S88-S97
19. Kunieda T, Simonaro CM, Yoshida M, Ikadai H, Levan G, Desnick RJ, Schuchman EH: Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation. Genomics 1995, 29:582-587
20. Beratis NG, Turner BM, Weiss R, Hirshhorn K: Arylsulfatase B deficiency in Maroteaux Lamy syndrome: cellular studies and carrier identification. Pediatr Res 1975, 9:475-480
21. He X, Chen F, Gatt S, Schuchman EH: An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease. Anal Biochem 2001, 293:204-211
22. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982, 126:131-138
23. Wang X, Manner PA, Horner A, Shum L, Tuan RS, Nuckolls GH: Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage. Osteoarthritis Cartilage 2004, 12:963-973
24. Cheon H, Yu SJ, Yoo DH, Chae IJ, Song GG, Sohn J: Increased expression of proinflammatory cytokines and metalloproteinase-1 by TGF-β1 in synovial fibroblasts from rheumatoid arthritis and normal individuals. Clin Exp Immunol 2002, 127:547-552
25. Simonaro C, Haskins ME, Kunieda T, Evans SM, Visser JW, Schuchman E: Bone marrow transplantation in newborn rats with mucopolysaccharidosis type VI: biochemical, pathological, and clinical findings. Transplantation 1997, 63:1386-1393
26. Cuschieri J, Billgren J, Maier RV: Phosphatidylcholine-specific phospholipase C (PC-PLC) is required for LPS-mediated macrophage activation through CD14. J Leukoc Biol 2006, 80:407-414
27. Cuschieri J, Bulger E, Billgrin J, Garcia I, Maier RV: Acid sphingomyelinase is required for lipid raft TLR4 complex formation. Surg Infect (Larchmt) 2007, 8:91-106
28. Ainola MM, Mandelin JA, Liljestrom MP, Li TF, Hukkanen MV, Konttinen YT: Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1beta. Clin Exp Rheumatol 2005, 23:644-650
29. Chen Q, Casali B, Pattacini L, Boiardi L, Salvarani C: Tumor necrosis factor-alpha protects synovial cells from nitric oxide induced apoptosis through phosphoinositide 3-kinase Akt signal transduction. J Rheumatol 2006, 33:1061-1068
30. Ortutay Z, Polgár A, Gömör B, Géher P, Lakatos T, Glant TT, Gay RE, Gay S, Pállinger E, Farkas C, Farkas E, Tóthfalusi L, Kocsis K, Falus A, Buzás E: Synovial fluid exoglycosidases are predictors of rheumatoid arthritis and are effective in cartilage glycosaminoglycan depletion. Arthritis Rheum 2003, 48:2163-2172
31. Doyle SL, O'Neill LA: Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006, 72:1102-1113
32. Palsson-McDermott EM, O'Neill LA: Signal transduction by the lipopolysaccharide receptor. Toll-like receptor-4. Immunology 2004, 113:153-162
33. Diks SH, Richel DJ, Peppelenbosch MP: LPS signal transduction: the picture is becoming more complex. Curr Top Med Chem 2004, 4:1115-1126
34. Triantafilou M, Triantafilou K: Receptor cluster formation during activation by bacterial products. J Endotoxin Res 2003, 9:331-335
35. Burrage PS, Mix KS, Brinckerhoff CE: Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543
36. Tardif G, Reboul P, Pelletier JP, Martel-Pelletier J: Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Mod Rheumatol 2004, 14:197-204
37. Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S, Toda A, Eyanagi R, Soeda S: Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Cell Immunol 2007, 245:24-31
38. Rigante D, Caradonna P: Secondary skeletal involvement in San Filippo syndrome. QJM 2004, 97:205-209
39. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS: Mechanisms of disease: the link between RANKL and arthritic bone disease. Rheumatology 2005, 1:47-54
40. Huwiler A, Zangemeister-Wittke U: Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit Rev Oncol Hematol 2007, 63:150-159
41. Migita K, Honda S, Yamasaki S, Hirai Y, Fukuda T, Aoyagi T, Kita M, Ida H, Tsukada T, Kawakami A, Kawabe Y, Eguchi K: Regulation of rheumatoid synovial cell growth by ceramide. Biochem Biophys Res Commun 2000, 269:70-75
42. Kim M-K, Lee H, Kwak J-Y, Park J-I, Yun J, Bae Y-S: Sphingosine-1- phosphate stimulates rat primary chondrocyte proliferation. Biochem Biophys Res Commun 2006, 345:67-73
43. Thomas JA, Jacobs S, Kierstein J, Van Hove J: Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome. J Inherit Metab Dis 2006, 29:762
44. Cox-Brinkman J, Smeulders MJ, Hollak CE, Wijburg FA: Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy. J Inherit Metab Dis 2007, 30:47-50